

**Notice Regarding Recalculated 340B Ceiling Prices for The Medicines Company Products
June 3, 2019**

The Medicines Company (MDCO) has recalculated 340B ceiling prices for the below products for the associated quarters between 1Q2015 and 3Q2016, as noted below.

MDCO has identified covered entities that may be eligible for potential payment based on the recalculated 340B ceiling prices by using chargeback data. For covered entities that may be owed more than \$1,000, MDCO will contact the covered entity’s primary contact as listed in the HRSA database to notify them of a potential payment correction. For covered entities that may be owed \$1,000 or less, they may seek a payment correction from MDCO by contacting Marisa DeChiaro at 973-290-6032 or marisa.dechiaro@themedco.com. MDCO will not seek reimbursement or corrections where 340B covered entities underpaid based on the recalculated prices.

MDCO has authorized the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the HRSA public website to ensure transparency by providing access to information about MDCO’s recalculation affecting certain 340B covered entities for the impacted products.

NDC	Product	Quarter
65293000101	Angiomax	1Q2015 - 3Q2016
65293000422	Angiomax	1Q2015 - 3Q2016
65293000211	Cleviprex	1Q2015 - 3Q2016
65293000255	Cleviprex	1Q2015 - 3Q2016
65293000511	Cleviprex	1Q2015 - 3Q2016
65293000555	Cleviprex	1Q2015 - 3Q2016
65293001106	Ionsys	3Q2015 - 3Q2016
65293000310	Kengreal	3Q2015 - 3Q2016
65293041125	Midazolam	1Q2015 - 3Q2016
65293041210	Midazolam	1Q2015 - 3Q2016
65293041310	Midazolam	1Q2015 - 3Q2016
65293041410	Midazolam	1Q2015 - 3Q2016
65293041510	Midazolam	1Q2015 - 3Q2016
65293041625	Midazolam	1Q2015 - 3Q2016
65293041725	Midazolam	1Q2015 - 3Q2016
65293001410	Minocin IV	3Q2015 - 3Q2016
65293037325	Ondansetron	1Q2015 - 3Q2016
65293037401	Ondansetron	1Q2015 - 3Q2016
65293001503	Orbactiv	1Q2015 - 3Q2016
65293042610	Rocuronium	1Q2015 - 3Q2016
65293042710	Rocuronium	1Q2015 - 3Q2016